News & Events

News

All categories

Earnings

Press Release

All years

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Pricing of Public Offering of Common Shares

November 8, 2019

Affimed Announces Proposed Public Offering of Common Shares

November 7, 2019

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

November 7, 2019

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

November 7, 2019

Affimed Reports Progress on Key Clinical Development Programs

October 15, 2019

Affimed to Participate in Investor Conferences in September

August 28, 2019

Affimed Reports Second Quarter 2019 Financial and Operational Results

August 7, 2019

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

July 31, 2019

Affimed Added to the Russell 2000®, 3000® and Microcap Indexes

July 1, 2019

Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019

June 24, 2019

Events

All

Scientific

Investors

29May

ASCO 2020 Annual Meeting

May 29 - June 2, 2020 (TBD)

25Aug

Innate Killer Summit 2020

August 25 - July 26, 2020 (San Diego, USA)
Presenter: Joachim Koch

Webcasts
More events

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.